Symbiotec Pharmalab's shares jumped 8.53% after the company disclosed receipt of the FDA Establishment Inspection Report for its Pithampur facility.
The FDA inspected the plant between Aug 10‑14, 2026, issuing a Voluntary Action Indicated classification, but the filing did not disclose specific observations or corrective actions.
In the June quarter, net profit fell 50% YoY to ₹14.1 cr from ₹29.9 cr, while EBITDA dropped to ₹45.2 cr from ₹58 cr, even as revenue rose 7% to ₹218.2 cr.
Profitability was dented by ₹23 cr in operating expenses and ₹12 cr in depreciation for new ventures that have yet to generate revenue.
The company projects 20‑25% growth in FY27 revenue and EBITDA, citing commercial milestones in the second half and a burgeoning biotechnology contract‑manufacturing arm. It has poured over ₹400 cr into fermentation‑based facilities, now nearing completion and expected to generate revenue in Q4, scaling further next year.
The 8% rally lifted the stock to ₹1,145.80, its highest since listing, reflecting optimism about FDA clearance and future revenue streams, though analysts remain wary of the current profitability squeeze.